Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER

por Yardley, D A, Tripathy, D, Brufsky, A M, Rugo, H S, Kaufman, P A, Mayer, M, Magidson, J, Yoo, B, Quah, C, Ulcickas Yood, M
Publicado 2014

Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer

por Viale, G., Basik, M., Niikura, N., Tokunaga, E., Brucker, S., Penault-Llorca, F., Hayashi, N., Sohn, J., Teixeira de Sousa, R., Brufsky, A.M., O’Brien, C.S., Schmitt, F., Higgins, G., Varghese, D., James, G.D., Moh, A., Livingston, A., de Giorgio-Miller, V.
Publicado 2023

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

por Hartmaier, R J, Trabucco, S E, Priedigkeit, N, Chung, J H, Parachoniak, C A, Vanden Borre, P, Morley, S, Rosenzweig, M, Gay, L M, Goldberg, M E, Suh, J, Ali, S M, Ross, J, Leyland-Jones, B, Young, B, Williams, C, Park, B, Tsai, M, Haley, B, Peguero, J, Callahan, R D, Sachelarie, I, Cho, J, Atkinson, J M, Bahreini, A, Nagle, A M, Puhalla, S L, Watters, R J, Erdogan-Yildirim, Z, Cao, L, Oesterreich, S, Mathew, A, Lucas, P C, Davidson, N E, Brufsky, A M, Frampton, G M, Stephens, P J, Chmielecki, J, Lee, A V
Publicado 2018